{"id":"W2034585843","doi":"10.1001/jama.290.23.3073","title":"Efalizumab for Patients With Moderate to Severe Plaque Psoriasis","year":2003,"lang":"en","type":"article","venue":"JAMA","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":397,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Efalizumab; Medicine; Psoriasis; Psoriasis Area and Severity Index; Dermatology Life Quality Index; Placebo; Adverse effect; Severity of illness; Internal medicine; Dermatology; Plaque psoriasis; Randomized controlled trial; Visual analogue scale; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005988699,0.0004914011,0.00140321,0.0002256043,0.0003763158,0.0003028322,0.0002174459,0.0006658667,0.003024653],"category_scores_gemma":[0.001002312,0.0001921044,0.0005961595,0.0002710249,0.0002372543,0.0002838739,0.0001597246,0.0008100484,0.0004754132],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002417502,"about_ca_system_score_gemma":0.000487682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006510783,"about_ca_topic_score_gemma":0.001592996,"domain_scores_codex":[0.9997607,0.0001148897,0.00002177305,0.00002832471,0.00003355677,0.00004062938],"domain_scores_gemma":[0.999688,0.00009668915,0.0000739598,0.00001140736,0.00002188454,0.000107924],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3429954,0.01024911,0.05902741,0.00473187,0.002077372,0.002491108,0.0003941419,0.001076325,0.03494101,0.0004236186,0.01481513,0.5267775],"study_design_scores_gemma":[0.3836351,0.234584,0.3222863,0.0007681795,0.003704539,0.009049713,0.000320136,0.002219215,0.005552971,0.0008682245,0.03693222,0.00007939019],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9577841,0.03365317,0.000618694,0.002169296,0.0003052135,0.0009703848,0.0003173837,0.00009890545,0.004082923],"genre_scores_gemma":[0.9904665,0.005681613,0.000779026,0.001277623,0.0003377812,0.0003085062,0.0002457668,0.000004708637,0.0008985149],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003024653,"threshold_uncertainty_score":0.01011854,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01132498776174481,"score_gpt":0.2192114849151484,"score_spread":0.2078864971534036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}